Supplementary materials

Table S1 Relationship between clinical characteristics and efficacy

Characteristic	Group	*n*	ORR, *n* (%)	DCR, *n* (%)	mPFS	mOS	mDOR
Location	Left-side	16	5 (31.25)	13 (81.25)	2.79	11.28	2.83
	Right-side	5	1 (20.00)	5 (100.00)	5.78	14.75	2.92
	P value		0.999	0.549	0.158	0.923	0.953
Treatment lines	3L	12	1 (8.33)	10 (83.33)	4.14	12.35	2.92
	≥ 4L	9	5 (55.56)	8 (88.89)	4.11	17.12	2.83
	P value		0.046	0.999	0.899	0.027	0.953
Lung metastases	Yes	13	2 (15.38)	10 (76.92)	4.11	11.86	11.14
	No	8	4 (50.00)	8 (100.00)	4.14	15.10	2.81
	P value		0.146	0.257	0.941	0.688	0.049
Liver metastases	Yes	13	4 (30.77)	12 (92.31)	4.14	12.84	2.87
	No	8	2 (25.00)	6 (75.00)	2.79	14.45	9.07
	P value		0.999	0.531	0.669	0.776	0.546
Previous cetuximab therapy	Yes	7	1 (14.29)	6 (85.71)	4.11	11.86	2.79
	No	14	5 (35.71)	12 (85.71)	4.14	13.80	2.92
	P value		0.613	0.999	0.206	0.160	0.247

n, number; ORR, objective response rate; DCR, disease control rate; mPFS, median progression-free survival; mOS, median overall survival; mDOR, median duration of response; NA, not available.

Table S2 Summary of adverse events

Group	TEAE *n* (%)	TRAE *n* (%)	irAE *n* (%)
All grade	21 (100.0)	21 (100.0)	11 (52.4)
Grade 1	21 (100.0)	20 (95.2)	7 (33.3)
Grade 2	19 (90.5)	16 (76.2)	5 (23.8)
≥ Grade 3	12 (57.1)	11 (52.4)	2 (9.5)
Causing the suspension of SCT200	10 (47.6)	9 (42.9)	1 (4.8)
Causing the suspension of SCT-I10A	5 (23.8)	5 (23.8)	4 (19.0)
Causing the withdrawal of SCT200	1 (4.8)	1 (4.8)	0
Causing the withdrawal of SCT-I10A	1 (4.8)	1 (4.8)	0

n, number; TRAE, treatment-related adverse event.

Table S3 Baseline characteristics in SCT200 plus SCT-I10A cohort and SCT200 monotherapy cohort

	SCT200 plus SCT-I10A cohort	SCT200 monotherapy cohort
	(*n* = 21)	(*n* = 25)
Age, *n* (%)		
< 65	14 (66.7)	24 (96.0)
≥ 65	7 (33.3)	1 (4.0)
Gender, *n* (%)		
Male	11 (52.4)	17 (68.0)
Female	10 (47.6)	8 (32.0)
ECOG, *n* (%)		
0	6 (28.6)	0
1	15 (71.4)	25 (100.0)
Location of the primary tumor, *n* (%)		
Left-side colon or rectum	16 (76.2)	NA
Right-side colon	5 (23.8)	NA
Number of organs with metastases, *n* (%)		
0	0	NA
1	7 (33.3)	NA
2	8 (38.1)	NA
≥3	6 (28.6)	NA
Previous cetuximab therapy, *n* (%)		
Yes	7 (33.3)	0
No	14 (66.7)	25 (100.0)

n, number; ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not available.

Table S4 Summary of TRAEs occurring in ≥ 20% of patients or all TRAEs of grade 3 or 4 in SCT200 plus SCT-I10A cohort and SCT200 monotherapy cohort

Adverse event	SCT200 plus SCT-I10A cohort *n* (%)		SCT200 monotherapy cohort *n* (%)	
	Any grade	≥ Grade 3	Any grade	≥ Grade 3
All	21 (100.0)	12 (57.1)	25 (100.0)	9 (36.0)
Hypomagnesemia	16 (76.2)	7 (33.3)	22 (88.0)	3 (12.0)
Acneiform dermatitis	9 (42.9)	2 (9.5)	24 (96.0)	2 (8.0)
Rash	10 (47.6)	2 (9.5)	0	0
Proteinuria	8 (38.1)	0	0	0
Hypoalbuminemia	1 (4.8)	0	0	0
Increased blood alkaline phosphatase	4 (19.0)	0	1 (4.0)	0
Hypercholesterolemia	0	0	3 (12.0)	0
Hyponatremia	0	0	0	0
Anemia	0	0	0	0
Increased alanine aminotransferase	2 (9.5)	0	9 (36.0)	0
Hypokalemia	1 (4.8)	1 (4.8)	0	0
Increased aspartate transferase	2 (9.5)	0	6 (24.0)	0
hypocalcemia	1 (4.8)	0	5 (20.0)	0
Paronychia	3 (14.3)	0	9 (36.0)	0
Chapped Skin	1 (4.8)	0	3 (12.0)	1 (4.0)
Hypertriglyceridemia	0	0	7 (28.0)	0
Leukopenia	1 (4.8)	0	5 (20.0)	0
Dry skin	1 (4.8)	0	4 (16.0)	1 (4.0)
Conjunctivitis	1 (4.8)	0	7 (28.0)	0
Hypophosphatemia	1 (4.8)	0	8 (32.0)	0

n, number.